pulmonary aspergillosis
UK biotech Pulmocide secures $30m for inhalable lung disease therapies
March 20, 2017Research and Development, Sales and Marketing pulmocide, pulmonary aspergillosis, respiratory syncytial virus
Pulmocide, a UK biotech run by a former GlaxoSmithKline scientists and based in London, has secured $30.4 million in Series …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
